****EVENT DRIVEN TRADERS' BOARD****

[funnyG986]

INKS AH merger 8k key items; high reward/risk biomedical start up reverse merger play. Investors in at @0.0137 per share

https://www.sec.gov/Archives/edgar/data/1062128/000117891316006375/zk1618936.htm

1. $590K cash from old INKS shell after the merger
a requirement that a concurrent financing of not less than $590,000 shall have occurred immediately prior to the Effective Time;

2. $500K new investment from a private investor at $0.0137 per share
In conjunction with the consummation of the Merger, the Company closed on a private placement through a securities purchase agreement executed on August 2, 2016 (the “Securities Purchase Agreement”) with an investor with respect to the sale of an aggregate of $500,000 of 3,580,531 shares of the Company’s common stock and 451 shares of the Company’s newly designated Series A Convertible Preferred Stock (the “Series A Preferred Stock”) (each share is convertible into 72,682.814 shares of the Company’s common stock).

3. 69M OS at the closing of merger + 2,562 shares of Series B + 451 shares Series A.
After the closing of the Merger, the Company had 69,754,123 shares of common stock issued and outstanding held by approximately 77 shareholders of record.

4. Appointment of Dana Wolf as our Chief Scientific Officer and Israel Alfassi as a director.
Dana Wolf was appointed as Chief Scientific Officer in August 2016 in conjunction with the closing of the Merger. From 2001 until the present, Prof. Wolf has served as the Head of Clinical Virology, and from 1996 until the present has served as a Senior physician for infectious diseases, at the Hadassah University Hospital in Jerusalem, Israel, where she had previously completed her Internal Medicine residency and her clinical fellowship in Infectious Diseases. Prof. Wolf has also served as the Director of National influenza center in Israel from 2002 until the present, as well as served on the National Advisory Committee on Immunization practices and Infectious Diseases from 2005 until the present. In addition, Prof. Wolf has been a member of the National Epidemics Preparedness Team from 2009 to the present and from 2008 to 2013 served on the National Laboratory Advisory Committee. In 2014, Prof. Wolf was the recipient of the Landau Prize for the Science and Performing Arts in the field of virology. Prof. Wolf holds an M.D from the Hadassah Hebrew University Medical School.

5. Company planned milestone
Artemis agreed to certain development milestones, including the completion of CMC development and manufacturing for Phase I by the fourth quarter of 2017, completion of Phase I by the fourth quarter of 2019, completion of Phase II by the fourth quarter of 2022 and the first regulatory submission by the fourth quarter of 2027. Additionally, Artemis agreed to certain investment milestones, including the requirement to obtain financing of not less than $700,000 within seven months of the Effective Time, $1 million within 12 months of the Effective Time and $2 million within 24 months of the Effective Time. In the event that Artemis fails to meet the development milestone and investment milestones as set forth in the License Agreement, Hadasit has the right to terminate the License Agreement.

6. Company shell status change
Following the consummation of the Merger described in Item 1.01 and Item 2.01 of this Current Report on Form 8-K, the Company believes that it is not a shell corporation as that term is defined in Rule 405 of the Securities Act and Rule 12b-2 of the Exchange Act.